Fujian Rongheng Pharmaceutical Co., Ltd.

In this study, the ibuprofen suspension (specification: 100 mL: 2 g) developed by Fujian Rongheng Pharmaceutical Co., Ltd. was used as the test preparation. According to the relevant regulations of bioequivalence studies, the ibuprofen suspension (specification: 100 mL: 2 g, trade name: Merlin®) produced by Shanghai Johnson & Johnson Pharmaceuticals Co., Ltd. was used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting/postprandial conditions.

To observe the relative bioavailability of a single oral dose of 40 mg (fasting/after meal) of the test preparation atorvastatin calcium tablets (specification: 40 mg/tablet, Hainan Hailing Chemical Pharmaceutical Co., Ltd.) and the reference preparation atorvastatin calcium tablets (Lipitor, specification: 40 mg/tablet, produced by Pfizer Pharmaceuticals Co., Ltd.) in healthy Chinese humans, analyze the pharmacokinetic parameters of the two preparations, and evaluate the bioequivalence of the two preparations.

The metformin hydrochloride sustained-release tablets (0.5 g) produced by Hainan Hailing Chemical Pharmaceutical Co., Ltd. was used as the test preparation, and the original manufacturer Bristol-Myers Squibb (500 mg, trade name: Glucophage®XR) was used as the reference preparation. The bioequivalence of the test preparation and the reference preparation when administered under fasting and postprandial conditions was evaluated.